| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/16/2006 | CA2575039A1 Novel cyclic amino benzoic acid derivative |
| 02/16/2006 | CA2575014A1 Crp lowering agent |
| 02/16/2006 | CA2575002A1 Hiv inhibiting 1,2,4-triazin-6-one derivatives |
| 02/16/2006 | CA2574997A1 Pharmaceutical composition comprising drospirenone and ethynylestradiol |
| 02/16/2006 | CA2574914A1 Organic compounds |
| 02/16/2006 | CA2574827A1 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
| 02/16/2006 | CA2574597A1 Alpha-ketoglutarates and their use as therapeutic agents |
| 02/16/2006 | CA2574292A1 Piperazine derivatives with ccr3 inhibiting activity |
| 02/16/2006 | CA2573848A1 Constrained cyano compounds |
| 02/16/2006 | CA2573686A1 Adhesive containing wound closure device and method |
| 02/16/2006 | CA2573682A1 Process for the preparation of a1 adenosine receptor agonists |
| 02/16/2006 | CA2573668A1 Ophthalmic compositions and methods for treating ophthalmic conditions |
| 02/16/2006 | CA2573644A1 Tetrapeptide analogs |
| 02/16/2006 | CA2573509A1 Histone deacetylase inhibitors |
| 02/16/2006 | CA2573386A1 Composition for promoting vascular smooth muscle relaxation |
| 02/16/2006 | CA2573369A1 Inhibitors of histone deacetylase |
| 02/16/2006 | CA2573332A1 Compositions and formulations of decitabine polymorphs and methods of use thereof |
| 02/16/2006 | CA2573091A1 Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| 02/16/2006 | CA2573066A1 Mercaptoimidazoles as ccr2 receptor antagonists |
| 02/16/2006 | CA2572865A1 Compositions and methods of use for treatment of mammalian diseases |
| 02/16/2006 | CA2572864A1 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| 02/16/2006 | CA2572752A1 Pyrazole derivatives for treating conditions mediated by activation of the adenosine a2b or a3 receptor |
| 02/16/2006 | CA2572745A1 Pyrazole amide derivatives, compositions containing such compounds and methods of use |
| 02/16/2006 | CA2572614A1 Pyrido-pyrido pyrimidine derivatives, preparation thereof, therapeutic use thereof for treating cancer |
| 02/16/2006 | CA2572325A1 Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide |
| 02/16/2006 | CA2571407A1 Amino acid derived prodrugs of propofol, compositions and uses thereof |
| 02/16/2006 | CA2571198A1 Progesterone receptor antagonist contraceptive regimens and kits |
| 02/16/2006 | CA2571143A1 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof |
| 02/16/2006 | CA2570863A1 Compositions containing nicorandil, preparation method and use |
| 02/16/2006 | CA2568850A1 Indolizine carboxamides and the aza and diaza derivatives thereof |
| 02/15/2006 | EP1626096A2 In vitro method of detecting a cell proliferative disorder involving fibroblast growth factor homologous factor-1 (FHF-1) |
| 02/15/2006 | EP1626086A2 Double-stranded nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| 02/15/2006 | EP1626084A1 Compositions and methods for the diagnosis of tumours |
| 02/15/2006 | EP1626058A1 Compositions and methods for the diagnosis of tumour |
| 02/15/2006 | EP1626051A1 Crystals of quinolinecarboxylic acid derivative solvate |
| 02/15/2006 | EP1626050A1 Sulfur-containing naphthoylimide derivatives |
| 02/15/2006 | EP1626048A1 Crystal of benzimidazole derivative and process for producing the same |
| 02/15/2006 | EP1626044A1 Novel piperidine derivative |
| 02/15/2006 | EP1626043A1 Heterocyclic thioesters |
| 02/15/2006 | EP1625860A1 Kit for applying drug coating to a medical device with a latex emulsion |
| 02/15/2006 | EP1625859A1 A process for the preparation of a package comprising a sterilised bulk of a substance, and a package comprising a sterilised bulk of a penicilin |
| 02/15/2006 | EP1625858A1 Compounds for treating ischemic tissue |
| 02/15/2006 | EP1625851A1 Preparation for preventing contact of pathogenic matter with living organism |
| 02/15/2006 | EP1625850A1 Immunostimulant |
| 02/15/2006 | EP1625849A1 Pharmaceutical composition comprising drospirenone and ethynylestradiol |
| 02/15/2006 | EP1625848A1 Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid |
| 02/15/2006 | EP1625847A1 Pharmaceutical composition comprising a tetrahydrotriazolo[4,3-a]pyrazine |
| 02/15/2006 | EP1625845A1 Adhesive preparation containing fentanyl |
| 02/15/2006 | EP1625378A2 Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
| 02/15/2006 | EP1625207A2 Compounds for treatment of inflammation, diabetes and related disorders |
| 02/15/2006 | EP1625143A1 Estratriene derivatives |
| 02/15/2006 | EP1625142A2 Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein |
| 02/15/2006 | EP1625140A2 Branched immunomodulatory compounds and methods of using the same |
| 02/15/2006 | EP1625135A2 Fondaparinux sodium composition of high purity |
| 02/15/2006 | EP1625128A2 Thermal energy storage |
| 02/15/2006 | EP1625124A1 Oxazolidinone derivatives as antimicrobials |
| 02/15/2006 | EP1625123A2 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
| 02/15/2006 | EP1625121A1 Pyrimidine derivatives for the treatment of abnormal cell growth |
| 02/15/2006 | EP1625111A2 Thyronamine derivatives and analogs and methods of use thereof |
| 02/15/2006 | EP1624936A1 Cns chloride modulation and uses thereof |
| 02/15/2006 | EP1624935A2 Anti-adhesion composites and methods os use thereof |
| 02/15/2006 | EP1624899A2 Increased transduction using abc transporter substrates and/or inhibitors |
| 02/15/2006 | EP1624896A2 Method for the production of a stable injectable formulation made of difficult to dissolve antineoplastic active substances |
| 02/15/2006 | EP1624893A2 Inhibitors of phosphodiesterases in infertility |
| 02/15/2006 | EP1624887A1 One or several enzyme-containing compounds, dietetic food products and drugs produced from said compounds and the use therefor for medical purposes |
| 02/15/2006 | EP1624882A2 Compositions for delivering peptide yy and pyy agonists |
| 02/15/2006 | EP1624880A2 Annatto extract compositions, including geranyl geraniols and methods of use |
| 02/15/2006 | EP1624879A2 Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage |
| 02/15/2006 | EP1624878A1 Use of compositions comprising an estrogenic component for the treatment and prevention of musculoskeletal pain |
| 02/15/2006 | EP1624877A2 Use of steroid derivatives for the treatment of angiotensin ii related diseases e.g. cardiovascular and proliferative disorders |
| 02/15/2006 | EP1624876A2 Selective testicular 11beta-hsd inhibitors and methods of use thereof |
| 02/15/2006 | EP1624875A2 Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine |
| 02/15/2006 | EP1624874A2 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 02/15/2006 | EP1624873A2 Use of tyrosine kinase inhibitors for treating cerebral ischemia |
| 02/15/2006 | EP1624872A2 Combination of a glycine/nmda antagonist and a tachykinin nk-1 receptor antagonist for use in the treatment of neurodegeneration |
| 02/15/2006 | EP1624871A1 Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions |
| 02/15/2006 | EP1624870A2 Dosage form containing (s)-pantoprazole as active ingredient |
| 02/15/2006 | EP1624869A2 Dosage form containing pantoprazole as active ingredient |
| 02/15/2006 | EP1624867A1 Further therapeutic use of zolpidem |
| 02/15/2006 | EP1624866A2 Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors |
| 02/15/2006 | EP1624863A1 Improvements in or relating to anti-aromatase composition |
| 02/15/2006 | EP1624862A2 Particulate materials |
| 02/15/2006 | EP1624861A2 Novel topical steroid cream formulations |
| 02/15/2006 | EP1624860A2 Drug formulations having reduced abuse potential |
| 02/15/2006 | EP1624858A2 Novel encochleation methods, cochleates and methods of use |
| 02/15/2006 | EP1624855A2 Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| 02/15/2006 | EP1624850A2 Compositions and methods for treatment of severe acute respiratory syndrome (sars) |
| 02/15/2006 | EP1624848A2 Methods of hormornal treatment utilizing extended cycle contraceptive regimens |
| 02/15/2006 | EP1624846A2 Inhibition of drug binding to serum albumin |
| 02/15/2006 | EP1624845A2 4',4''-substituted 3alpha-(diphenylmethoxy)tropane analogs for treatment of mental disorders |
| 02/15/2006 | EP1624753A2 Purinergic modulation of smell |
| 02/15/2006 | EP1624752A2 Delivery of compounds with rehydrated blood cells |
| 02/15/2006 | EP1487456B1 Benzenesulphonate salt of a morpholine urea derivative for use as a ccr-3 antagonist in the treatment of inflammatory conditions |
| 02/15/2006 | EP1453835B1 Adenosine a 2a receptor antagonists |
| 02/15/2006 | EP1441739B1 Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder |
| 02/15/2006 | EP1399468B1 2-((n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl)-amino)-alkylboronic acid derivatives |
| 02/15/2006 | EP1365743B1 Fast dissolving tablets |
| 02/15/2006 | EP1341533B1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 02/15/2006 | EP1268493B1 Phosphoramidate prodrugs |
| 02/15/2006 | EP1267865B1 Amiodarone-containing parenteral solution |